The symptoms (itching, photophobia, lacrimation, pain) and signs (conjunctival hyperemia /chemosis, size of giant papillae, limbal infiltrate, shield ulcers/keratitis and trantas dots were recorded.
Treatment was defined as successful when there was general reduction or complete resolution of symptoms and signs such as reduction in size of giant papillae to less than one millimeter, conjunctiva hyperemia and limbal infiltrates to less than 50%, reduction in number of trantas dots to less than 50% and reduction in size of keratitis to less than 50%.
All patients had conjunctival hyperemia followed by limbal infiltrate and trantas dots (83.87%) each.
of Patients (Percentage) Symptoms & Signs Topical Supratarsal Topical 0.1% Steroids triamcinolone Cyclosporine (Difluprednate) / Tacrolimus Group I Group II Group III Severe itching 26 (100%) 26 (100%) 15 (57%) Ropy Discharge 26 (100%) 26 (100%) 13 (50%) Photophobia 26 (100%) 26 (100%) 20 (77%) Large papillae 20 (77%) 25 (97%) 1 (3%) Horner
Trantas dots 26 (100%) 26 (100%) 8 (30%) Active shield ulcer 18 (69%) 25 (96%) 0 (3%) Limbal Pannus 26 (100%) 26 (100%) 10 (30%) Table II.